Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck Cancer

Author:

Noortman Wyanne A.12ORCID,Aide Nicolas3,Vriens Dennis1ORCID,Arkes Lisa S.14,Slump Cornelis H.2,Boellaard Ronald5,Goeman Jelle J.6,Deroose Christophe M.7ORCID,Machiels Jean-Pascal89,Licitra Lisa F.10,Lhommel Renaud11,Alessi Alessandra12,Woff Erwin13,Goffin Karolien7ORCID,Le Tourneau Christophe14ORCID,Gal Jocelyn15ORCID,Temam Stéphane16,Delord Jean-Pierre17,van Velden Floris H. P.1ORCID,de Geus-Oei Lioe-Fee1218ORCID

Affiliation:

1. Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands

2. TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands

3. Nuclear Medicine Department, Centre Hospitalier Universitaire de Caen, 14000 Caen, France

4. Technical Medicine, Delft University of Technology, 2628 CD Delft, The Netherlands

5. Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands

6. Department of Biomedical Data Sciences, Leiden University Medical Center, 2300 RC Leiden, The Netherlands

7. Nuclear Medicine and Molecular Imaging, Department of Imaging & Pathology, University Hospitals Leuven, KU Leuven, 3000 Leuven, Belgium

8. Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium

9. Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium

10. Department of Head and Neck Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, 20133 Milan, Italy

11. Division of Nuclear Medicine, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, 1200 Brussels, Belgium

12. Department of Nuclear Medicine-PET Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy

13. Nuclear Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B.), 1070 Bruxelles, Belgium

14. Department of Drug Development and Innovation, Institut Curie, Paris-Saclay University, 75005 Paris, France

15. Epidemiology and Biostatistics Department, Centre Antoine Lacassagne, University Côte d’Azur, 06100 Nice, France

16. Department of Head and Neck Surgery Gustave Roussy, 94805 Villejuif, France

17. Department of Medical Oncology, IUCT-Oncopole, 31100 Toulouse, France

18. Department of Radiation Science & Technology, Delft University of Technology, 2628 CD Delft, The Netherlands

Abstract

Aim: To build and externally validate an [18F]FDG PET radiomic model to predict overall survival in patients with head and neck squamous cell carcinoma (HNSCC). Methods: Two multicentre datasets of patients with operable HNSCC treated with preoperative afatinib who underwent a baseline and evaluation [18F]FDG PET/CT scan were included (EORTC: n = 20, Unicancer: n = 34). Tumours were delineated, and radiomic features were extracted. Each cohort served once as a training and once as an external validation set for the prediction of overall survival. Supervised feature selection was performed using variable hunting with variable importance, selecting the top two features. A Cox proportional hazards regression model using selected radiomic features and clinical characteristics was fitted on the training dataset and validated in the external validation set. Model performances are expressed by the concordance index (C-index). Results: In both models, the radiomic model surpassed the clinical model with validation C-indices of 0.69 and 0.79 vs. 0.60 and 0.67, respectively. The model that combined the radiomic features and clinical variables performed best, with validation C-indices of 0.71 and 0.82. Conclusion: Although assessed in two small but independent cohorts, an [18F]FDG-PET radiomic signature based on the evaluation scan seems promising for the prediction of overall survival for HNSSC treated with preoperative afatinib. The robustness and clinical applicability of this radiomic signature should be assessed in a larger cohort.

Funder

Boerhinger Ingelheim France

Publisher

MDPI AG

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3